<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570622</url>
  </required_header>
  <id_info>
    <org_study_id>CIRRPIO</org_study_id>
    <nct_id>NCT00570622</nct_id>
  </id_info>
  <brief_title>Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis</brief_title>
  <official_title>Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the response to pioglitazone on the hepatic&#xD;
      venous pressure gradient and peripheral vascular responsiveness to vasoconstrictors in&#xD;
      patients with advanced (Child´s Grade B or C) cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cirrhotic liver disease is associated with portal hypertension including elevated portal&#xD;
      pressure as well as hyperdynamic circulation and low peripheral vascular resistance.&#xD;
      Endothelial nitric (NO) release is impaired in liver microvasculature, upregulation of eNOS&#xD;
      activity in the cirrhotic liver may constitute a new strategy to correct the increased&#xD;
      hepatic vascular tone in these patients. In contrary to this impaired endothelium-dependent&#xD;
      relaxation (endothelial dysfunction) and NO deficiency in the cirrhotic liver, systemic and&#xD;
      splanchnic circulation of cirrhotic patients is characterized by increased vascular tone and&#xD;
      hyporesponsiveness to vasoconstrictors. In addition to increasing insulin sensitivity,&#xD;
      thiazolidinediones, like pioglitazone decrease oxidative stress and inflammation and improve&#xD;
      endothelial function. In a randomized controlled, parallel group double-blind study 20&#xD;
      Patients with advanced (Child´s Grade B or C) liver cirrhosis will receive pioglitazone or&#xD;
      placebo for nine days. Portal hemodynamics and forearm blood flow response will be measured&#xD;
      at baseline and after pioglitazone/placebo to investigate the effect of pioglitazone in these&#xD;
      group of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>portal and systemic hemodynamic parameters</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>markers of oxidative stress (malondialdehyde)</measure>
    <time_frame>9 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Ascites</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 60mg of pioglitazone once a day orally for 9 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive Placebo orally once a day for 9 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Patients receive 60mg of pioglitazone once a day orally for 9 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo once a day orally for 9 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cirrhosis, grade B or C (Child-Pugh score)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to the trial drugs and contrast agent or to drugs with a&#xD;
             similar chemical structure&#xD;
&#xD;
          -  Treatment with vasoactive or non-steroidal anti-inflammatory drugs or systemic&#xD;
             antibiotics one week before the study&#xD;
&#xD;
          -  Exclusion criteria for hepatic hemodynamic investigation&#xD;
&#xD;
          -  Cardiac, renal or respiratory failure&#xD;
&#xD;
          -  Previous surgical or transjugular intrahepatic portosystemic shunt&#xD;
&#xD;
          -  Insulin-dependent diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnulf Ferlitsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Internal Medicine III, Gastroenterology and Hepatology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Ferlitsch A, Pleiner J, Mittermayer F, Schaller G, Homoncik M, Peck-Radosavljevic M, Wolzt M. Vasoconstrictor hyporeactivity can be reversed by antioxidants in patients with advanced alcoholic cirrhosis of the liver and ascites. Crit Care Med. 2005 Sep;33(9):2028-33.</citation>
    <PMID>16148476</PMID>
  </reference>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>December 10, 2007</study_first_submitted>
  <study_first_submitted_qc>December 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2007</study_first_posted>
  <last_update_submitted>November 24, 2008</last_update_submitted>
  <last_update_submitted_qc>November 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Arnulf Ferlitsch, MD</name_title>
    <organization>Gastroenterology and Hepatology, Medical University of Vienna</organization>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>pioglitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

